U.S. Markets open in 52 mins

Coherus BioSciences, Inc. (CHRS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
12.65-0.32 (-2.47%)
At close: 04:00PM EDT
12.65 0.00 (0.00%)
Pre-Market: 04:37AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close12.97
Bid12.02 x 1800
Ask15.27 x 800
Day's Range12.51 - 13.17
52 Week Range5.60 - 19.32
Avg. Volume1,123,377
Market Cap971.335M
Beta (5Y Monthly)1.13
PE Ratio (TTM)N/A
EPS (TTM)-3.12
Earnings DateFeb 22, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.29
  • Motley Fool

    Coherus BioSciences (CHRS) Q2 2022 Earnings Call Transcript

    This release can be found on the Coherus BioSciences website and is also attached to our Form 8-K. Today's call includes forward-looking statements regarding Coherus' current expectations about future events. All these forward-looking statements involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance or achievements to differ from results, performance or achievements implied by the forward-looking statements.

  • Zacks

    Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

    Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 32.29% and 3.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update

    – Commercial launch of CIMERLI™ planned for early October 2022 –– PDUFA date for toripalimab BLA is December 23, 2022 –– Commercial preparation underway for planned July 2023 launch of YUSIMRY™ –– UDENYCA® delivers 2nd quarter 2022 net sales of $60.1 million –– Conference call today at 5 p.m. ET – REDWOOD CITY, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reported financial results for the quarter ended June 30, 2022 and recent